Amid current economic uncertainties, investing in defensive stocks appears as your best bet for stability, especially if a ...

Spravato has been approved since 2019 for ... by its cost and a requirement for two hours of patient observation after administration. They suggest other fast-acting antidepressants could offer ...

Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.

FDA's rejection of MDMA therapy for PTSD doesn't dampen hopes for other psychedelic treatments. Read more here.

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...